Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 3 of the 46 sources its claims cite were checked for support.

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Open access

Abstract

Objective: To compare the efficacy and safety of sacituzumab tirumotecan (sac-TMT) with docetaxel in patients with locally advanced or metastatic epidermal growth factor receptor ( EGFR) -mutated non-small cell lung cancer (NSCLC) after previous treatment failure with EGFR-tyrosine kinase inhibitors and platinum based chemotherapy. Design: Multicentre, open label, randomised controlled trial. Setting: 48 centres in China, 1 September 2023 to 31 December 2024. Participants: 137 adults (aged 18-75 years) with EGFR -mutated advanced or metastatic NSCLC after previous treatment failure with EGFR-tyrosine kinase inhibitors and platinum based chemotherapy. Intervention: Patients were randomly assigned (2:1) to receive sac-TMT (5 mg/kg) on days 1 and 15 of each four week cycle, or docetaxel (75 mg/m 2 ) on day 1 of each three week cycle. Patients in the docetaxel group were permitted to crossover to sac-TMT treatment on disease progression. Main outcome measures: The primary endpoint was objective response rate as assessed by a blinded independent review committee (BIRC). The secondary endpoints included objective response rate assessed by the investigator; disease control rate, progression-free survival, time to response, and duration of response assessed by BIRC and the investigator; overall survival; and safety. Results: 137 patients were randomised to receive sac-TMT (n=91) or docetaxel (n=46). Median follow-up was 12.2 months at the data cut-off for efficacy (31 December 2024). BIRC assessed objective response rate was significantly higher in the sac-TMT group (45% (41/91)) v docetaxel (16% (7/45)), with a difference of 29% (95% confidence interval (CI) 15% to 43%; one sided P<0.001). Median progression-free survival was longer with sac-TMT than with docetaxel assessed by BIRC (6.9 v 2.8 months; hazard ratio 0.30, 95% CI 0.20 to 0.46; one sided P<0.001) and the investigator (7.9 v 2.8 months; hazard ratio 0.23, 0.15 to 0.36; one sided P<0.001). The 12 month overall survival rate was 73% with sac-TMT and 54% with docetaxel (hazard ratio 0.49, 0.27 to 0.88; one sided P=0.007). After adjustment for crossover using the rank-preserving structural failure time model, sac-TMT also showed improved overall survival (hazard ratio 0.36, 0.20 to 0.66). Grade ≥3 treatment related adverse events were less frequent with sac-TMT than with docetaxel (56% v 72%), with no new safety signals identified. Conclusions: Sac-TMT showed statistically significant and clinically meaningful improvements in objective response rate, progression-free survival, and overall survival compared with docetaxel, with a manageable safety profile in patients with EGFR -mutated locally advanced or metastatic NSCLC. Trial registration: ClinicalTrials.gov NCT05631262 .

Overview

CoChat Summary

## TL;DR

In this phase 2 multicentre open-label randomized trial in China, sacituzumab tirumotecan (sac-TMT) outperformed docetaxel in previously treated EGFR-mutated advanced NSCLC, improving objective response rate, progression-free survival, and overall survival. The safety profile was described as manageable, though treatment-related adverse events remained common in both groups.

## Key findings

  • Among 137 randomized patients, the BIRC-assessed objective response rate was 45% (41/91) with sac-TMT versus 16% (7/45) with docetaxel, a 29% absolute difference (95% CI 15% to 43%; one-sided P<0.001).
  • Median BIRC-assessed progression-free survival was 6.9 months with sac-TMT versus 2.8 months with docetaxel (hazard ratio 0.30, 95% CI 0.20 to 0.46; one-sided P<0.001).
  • At the interim overall survival analysis with 46 events (~34% maturity), the 12-month overall survival rate was 73% with sac-TMT versus 54% with docetaxel; the reported hazard ratio for death was 0.49 (95% CI 0.27 to 0.88; one-sided P=0.007).
  • Safety was mixed: grade ≥3 treatment-related adverse events occurred in 56% (51/91) with sac-TMT versus 72% (33/46) with docetaxel; febrile neutropenia occurred in 0% versus 20%, respectively.

## Methods

  • Design: Phase 2, multicentre, open-label, randomized controlled trial (OptiTROP-Lung03 part II) conducted at 48 centres in China; patients were randomized 2:1 to sac-TMT or docetaxel, stratified by brain metastases.
  • Sample/data: 137 patients aged 18 to 75 years with histologically or cytologically confirmed non-squamous, locally advanced or metastatic EGFR-mutated NSCLC that had progressed after EGFR-TKIs and platinum chemotherapy; all 137 received at least one dose and were included in safety analyses.
  • Main analysis: Primary endpoint was BIRC-assessed objective response rate; secondary endpoints included investigator-assessed response, disease control, progression-free survival, overall survival, and safety. Time-to-event outcomes were analyzed with Kaplan-Meier methods, stratified log-rank tests, and Cox models; overall survival was also adjusted for crossover using supplementary analyses.

## Limitations

  • The paper states that the sample size was modest for a phase 2 trial and that all enrolled patients were Chinese, which may limit generalisability.
  • The study used objective response rate as a surrogate primary endpoint, and the paper states it was not adequately powered for overall survival.
  • The paper states that quality of life was not included; additionally, the open-label design makes treatment awareness unavoidable, although blinded central review was used for the primary endpoint.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmj-2025-085680

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Trial profile. *Four patients had radiology detected disease progression verified by blinded independent review committee (BIRC). sac-TMT=sacituzumab tirumotecan
Fig 1 Trial profile. *Four patients had radiology detected disease progression verified by blinded independent review committee (BIRC). sac-TMT=sacituzumab tirumotecanCC BY-NC · PubMed Central
Fig 2 Waterfall plots showing antitumour activity assessed by blinded independent review committee in patients with EGFR-mutated non-small cell lung cancer. EGFR=epidermal growth factor receptor; sac-TMT=sacituzumab tirumotecan
Fig 2 Waterfall plots showing antitumour activity assessed by blinded independent review committee in patients with EGFR-mutated non-small cell lung cancer. EGFR=epidermal growth factor receptor; sac-TMT=sacituzumab tirumotecanCC BY-NC · PubMed Central
Fig 3 Time to response and duration of response in patients with EGFR-mutated non-small cell lung cancer according to treatment. PR=partial response; sac-TMT=sacituzumab tirumotecan
Fig 3 Time to response and duration of response in patients with EGFR-mutated non-small cell lung cancer according to treatment. PR=partial response; sac-TMT=sacituzumab tirumotecanCC BY-NC · PubMed Central
Fig 4 Kaplan-Meier curves for progression-free survival and overall survival in patients with EGFR-mutated non-small cell lung cancer receiving sac-TMT or docetaxel. (Panel A) Progression-free survival assessed by blinded independent review committee; (panel B) progression-free survival assessed by investigator; (panel C) overall survival; and (panel D) overall survival using RPSFT model to adjust for crossover effects. BIRC=blinded independent review committee; CI=confidence interval; EGFR=epidermal growth factor receptor; NE=not evaluable; NR=not reached; RPSFT=rank-preserving structural failure time; sac-TMT=sacituzumab tirumotecan
Fig 4 Kaplan-Meier curves for progression-free survival and overall survival in patients with EGFR-mutated non-small cell lung cancer receiving sac-TMT or docetaxel. (Panel A) Progression-free survival assessed by blinded independent review committee; (panel B) progression-free survival assessed by investigator; (panel C) overall survival; and (panel D) overall survival using RPSFT model to adjust for crossover effects. BIRC=blinded independent review committee; CI=confidence interval; EGFR=epidermal growth factor receptor; NE=not evaluable; NR=not reached; RPSFT=rank-preserving structural failure time; sac-TMT=sacituzumab tirumotecanCC BY-NC · PubMed Central

Verification

Claims the paper makes

2 Valid · 2 Not valid · 31 Not checked · 95 Own results and interpretations

64 more claims

Create a free account to see all 130 claims and to verify the 43 references still open.

See all claims — free account
  • Probably not a substantial claim. 31
  • It may state two separate claims as one. 37
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 29 references

Cited by

See all 51

Metadata

Authors
Fang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., Luo, Y., Zhang, Z., Song, X., Yang, R., Yang, J., Jin, X., Diao, Y., Ge, J., & Zhang, L.
Affiliations
  • Department of Medical Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, China
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Zhengzhou University (CN)
  • Shandong Tumor Hospital (CN)
  • Sheng Jing Hospital (CN)
  • First Affiliated Hospital of Nanchang University (CN)
  • Sichuan Cancer Hospital (CN)
  • Fujian Provincial Cancer Hospital (CN)
  • Zhejiang Cancer Hospital (CN)
  • Peking University Cancer Hospital (CN)
  • Hunan Cancer Hospital (CN)
  • First Affiliated Hospital of Henan University of Science and Technology (CN)
  • Shanxi Provincial Cancer Hospital (CN)
  • Kunming Medical University (CN)
  • Kelun Group (China) (CN)
  • National Engineering Research Centre of Targeted Biologics, Chengdu, China
  • Sun Yat-sen University (CN)
Corresponding author
Zhang, Li
Venue
BMJ
Publisher
BMJ
Published
2025-06-05
Volume
389
Pages
e085680
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4411054093
Cited by
51
References
29
Citations by year
2026: 40 · 2025: 11
FWCI
33.53
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
sacituzumab tirumotecan, docetaxel, EGFR-mutant non-small cell lung cancer, EGFR tyrosine kinase inhibitors, platinum-based chemotherapy, second-line therapy, objective response rate, progression-free survival, overall survival, treatment safety, EGFR tyrosine kinase inhibitor resistance
MeSH terms
Docetaxel, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. https://app.cochat.ai/papers/10.1136/bmj-2025-085680
The paper
Fang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., Luo, Y., Zhang, Z., Song, X., Yang, R., Yang, J., Jin, X., Diao, Y., Ge, J., & Zhang, L. (2025). Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ. https://doi.org/10.1136/bmj-2025-085680

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.